A wealth of transcriptomic and clinical data on breast and ovarian cancers are underutilized due to unharmonized data storage and format. We have developed the MetaGxData package compendium, which includes manually-curated and standardized clinical, pathological, survival, and treatment metadata across both breast and ovarian cancer microarray data. MetaGxData is the largest compendium of breast and ovarian microarray data to date, spanning 65 datasets and encompassing 13,756 samples. Standardization of metadata across the two cancer types promotes the use of their expression datasets in a variety of cross-tumour analyses, including identification of common biomarkers, establishing common patterns of co-expression networks, assessing the validity of prognostic signatures, and the identification of new consensus signatures that reflects upon common biological mechanisms. Here, we present our flexible framework, unified nomenclature, as well as applications that demonstrate the analytical power that is harnessed by combining breast and ovarian cancer datasets.
INTRODUCTION
4 curatedOvarianData data package, onto which we have added 5 expression datasets to the originally published version (24), for a total of 26 microarray datasets spanning 3,752 samples. To obtain these datasets we first used the curatedOvarianData pipeline to generate the "FULLcuratedOvarianData" version of the package, which differs from the public version in that probe sets for the same gene are not merged (https://bitbucket.org/lwaldron/curatedovariandata). Subsequently, the createEsets.R script and patientselection.config scripts were used with default parameters to generate the updated expression datasets of curatedOvarianData.
Curation
Gene and clinical annotations in the source data compendium were standardized within, but not between, breast and ovarian cancers, which could prevent easy integration across cancer types. We therefore developed semi-automatic curation scripts (24) to standardize gene and clinical annotations of all our datasets based on the nomenclature used in TCGA (2) [Supplementary Figure 3 ]. We also provide tumour-specific and critical annotations for each tumour type, including biomarker identification status (HER2, ER, PR), as well as treatment information when available [ Figure 3 ].
Processing of Gene Expression Datasets
The processing of ovarian cancer microarray datasets was previously described (24); breast cancer datasets were processed using in-house R/Bioconductor scripts (see Research Replicability). We used GEO platform descriptions as the primary source of probe and gene annotations when available, otherwise original annotations as published by the authors were used for non-standard gene expression profiling platforms. The full set of gene annotation platforms across all expression sets is provided in Table 1 .
Gene symbols and Entrez Gene identifiers that matched the probeset ids of a given expression set were subsequently saved as part of the featureData (fData) pertaining to that expression set. For genes with multiple probesets, the collapseRows function of the WGCNA package (version 1.42) was used to identify representative probesets with the highest variance across all dataset, using Entrez Gene identifiers as group labels. Users can select these representative probesets during the probe-gene mapping procedure for their subsequent mapping to either Entrez Gene Ids or gene symbols.
Replicate Identification and Removal
Our pipeline handles fast and flexible generation of fully curated expression datasets while providing users the option of removal of sample replicates. To facilitate quick selection of duplicates for exclusion from the expression datasets, we first generated a pre-computed set of biological and/or technical replicates for a given sample across all datasets. For every tumour type, a merged expressionSet object was first created by combining all the genes and samples across all expression datasets available. Quantile normalization was employed to removal between-platform batch effects, using the normalizeBetweenArrays function from the limma package (version 3.22.4). Replicates were identified based on samples that shared correlated expression profiles, selecting replicates sharing a Spearman correlation ≥0.98. The list of replicates generated per samples was saved as pre-computed 'duplicates' column as part of the phenoData (pData) for every sample in every expression set. The development of a pre-computed duplicates list for every sample facilities rapid filtering of these samples from expression sets according to user specifications.
Versatile Generation of Finalized Expression Datasets
To facilitate meta-analyses involving either selected studies or all the datasets presented in the MetaGxData compendium packages, selection and filtering of the finalized, curated datasets can be performed according to user specifications. We adapted the createEsetList.R script and patientselection.config parameter file from curatedOvarianData to expedite sample selection based on properties of patients and datasets. Users can select representative probesets across all samples of a particular dataset prior to probe-gene identifier conversion. Users are also provided options for filtering samples or sample replicates across all datasets based on certain criteria, such as the prevalence of particular survival data. Importantly, we also provide users the ability to specifically select for only primary tumour samples or several tissue types (primary tumours, healthy tissue, etc.).
Collectively, our data compendium, referred to as MetaGxData, encompasses 65 processed gene expression datasets, containing in total 13,756 breast and ovarian samples [Table 1, Figure 2] . Expression datasets are represented as S4 ExpressionSet objects with attached clinical data (pData), and feature data (fData) for fast and flexible analysis with R/Bioconductor (29).
USAGE AND UTILITY
MetaGxData serves as a large-scale, standardized compendium of genomic data for aggressive subtypes of women's cancers. The MetaGxData compendium is a flexible and adaptable resource that promotes selection of individual samples and datasets that match the users' requirements, and facilitates rapid integration of new datasets into the existing framework [ Table 2 ]. These combined strengths promote rigorous management of the current datasets at the user and maintainer levels, as well as easy extension of newer studies into the package in future iterations of MetaGxData.
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Enhancements in Data Assimilation and Annotation within MetaGxData
We have extended and standardized the curatedOvarianData processing pipeline across both breast and ovarian cancers. These enhancements have ensured that the MetaGxData processing framework is consistent across cancer types instead of singular cancer datasets. The processing framework includes the following features:
-Creation and standardization of a probe-gene mapping repository based on platform annotation files and original gene annotation files, across all datasets. Any new dataset that is incorporated into MetaGxData is matched against its corresponding annotation platform, facilitating quick mapping of gene annotations against probeset identifiers of the raw data. -Pre-computed identification and filtering of the 'best probe' for probe-gene mapping of gene expression data. The selected probe is identified and labelled as part of the "fData" slot of the ExpressionSet object for a given dataset. During the probe-gene mapping procedure, the user has the option to select for these probesets and map them against Entrez Gene identifiers or gene symbols. -Pre-computed and rapid identification of duplicated samples using a correlationbased matrix of the samples across all datasets. Duplicate samples are labelled in a 'duplicates' column within the fData slot of each dataset. When loading the gene expression datasets, the user has the option to remove these duplicate samples. Box 1: List of salient features offered as part of MetaGxData curation and assimilation of datasets.
Analysis of the Prognostic Value of Individual Genes in Breast and Ovarian Cancer
The wealth and breadth of transcriptomic datasets in MetaGxData will serve as a solid framework for translational cancer research. As an example of the versatility of our packages, we conducted a meta-analysis of the prognostic value of well-studied and prognostic genes in both breast and ovarian cancers, using the MetaGxBreast and MetaGxOvarian packages [ Figure 4 , Figure 5 ]. A total of 13 prognostic genes were tested, including 7 for breast cancer (ESR1, ERBB2, STAT1, CASP3, PLAU, VEGF, and AURKA) (30, 31) and 6 for ovarian cancer (PTCH1, TGFBR2, CXCL14, POSTN, FAP, and NUAK1) (32, 33). Datasets and samples were selected for meta-analysis dependent on the availability of survival events. For breast cancer, we used recurrence-free survival as the primary endpoint; when recurrence-free survival was unavailable, we used distant metastasis-free survival. This produced a cohort of 2,749 breast cancer patients from 16 datasets. For ovarian cancer, overall survival was used as the primary endpoint, resulting in a total of 2,630 ovarian cancer patients from 17 datasets. For the selected datasets the expression of each gene was median-dichotomized into high and low expression. Cox proportional hazards analysis was performed using the R package 7 survcomp (version 1.18.0) (34) to estimate the prognostic value (hazard ratio) and significance (corresponding p-value) for each dichotomized gene expression. The R package metafor (version 1.9-7) (35) was used to produce a random-effects metaanalytical estimate of the log hazard ratio, using the restricted maximum-likelihood estimator.
An assessment of the prognostic value of single genes using the MetaGxBreast and MetaGxOvarian packages provides both dataset-and gene-centric views towards determining prognostic value of genes in breast and ovarian cancer Table 2 ]. This supports our previous findings regarding the importance of this gene in biology-driven signatures of breast cancer, and its comparable prognostic effect with other multi-gene prognostic signatures (23, 36). We have also observed that the NUAK1 genes exhibits worst prognosis in ovarian cancer [ Figure 5 , Supplementary Table 3] . We have previously demonstrated the utility of NUAK1 in the development of a debulking signature that can predict the outcome of cytoreductive surgery (32).
Meta-Analysis of Gene Expression Prognosis Across Breast and Ovarian Cancer
Our single-gene prognostic analysis can be easily extended to a genome-wide metaanalysis. To this end, we determined the prognostic capability of 11,386 genes that are common to both the ovarian and breast cancer datasets [ Figure 6 , Supplementary Table 4] . We identified 58 genes that are significantly prognostic across both tumours (False Discovery Rate [FDR] < 5%). Of these, we identified 15 genes for which elevated expression values indicate worse prognosis in both cancers (HR>1), and 14 genes for which it indicates better prognosis (HR<1). Such findings will be integral in future studies of parallels between breast and ovarian cancer subtypes, for example, comparing basallike breast cancer and high-grade serous ovarian cancer (HG-SOC)(9).
Research Replicability
All the code required to reproduce the single-gene prognosis analysis, as well as the genome-wide meta-analysis, is publicly available on https://github.com/bhklab/MetaGxData. The procedure to setup the software environment and run our analysis pipeline is also provided on the github repository. This work complies with the guidelines proposed by Robert Gentleman (37) in terms of code availability and reproducibility of results.
DISCUSSION
Meta-analysis and data integration across breast and ovarian cancers is an area of intense research supporting common biology between these malignancies. We provide an integrative, standardized, and comprehensive platform to facilitate analysis between breast and ovarian cancer types and subtypes. This platform provides a flexible . CC-BY-NC-ND 4.0 International license peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052910 doi: bioRxiv preprint first posted online May. 12, 2016;  framework for data assimilation and unified nomenclature, with standardized data packages hosting the largest compendia of breast (10,004 samples) and ovarian (3,752 samples) cancer transcriptomic and clinical datasets available to date.
Integration of genomic data into standardized frameworks is challenged by the inconsistency of the clinical curations across datasets and across tumour types. Annotation of clinicopathological variables may vary widely due to different protocols in different laboratories, institutions, and across international boundaries. We have standardized, as much as possible, the catalog of variables within each tumour type. For characteristics pertaining to a specific tumour type, including ER, PGR, and HER2 IHC status in breast cancer samples, we have generated a semantic positive/negative variable to reflect IHC status. This facilitates searching across all patients irrespective of the original assay annotations, some of which may have been binary, or may have been on a 0-3 scale, or may have been qualitative. Similarly, a boolean y/n variable has been assigned to ovarian cancer patients to reflect whether they had been treated with platin, taxol, or neoadjuvant therapy. Many of the annotated variables (for example, those variables representing stage and tumour grade in MetaGxOvarian) have also been standardized to facilitate comparisions across multiple studies, and further analyzes using our previously developed packages (curatedOvarianData) have indicated good consistency across datasets, and ultimately facilitated uniform and consistent investigations on the prognostic effect of biomarkers in ovarian cancer survival (38,39).
The MetaGxData processing framework standardized annotations within a specific tumour type and subsequently extended that across tumour types. To this end we have included relevant categorical variables that reflect upon tumour histology in both tumour types (for example, tumour grade). The package also hosts a number of categorical and numerical variables that are crucial for survival analysis and prognostication of breast and ovarian cancer. Our MetaGxBreast and MetaGxOvarian packages follow a unified framework that facilitates integration of oncogenomic and clinicopatholgical data. We have demonstrated how our packages facilitate easy metaanalysis of gene expression and prognostication in both breast and ovarian cancers. This has the potential to serve as an important resource and a primer towards the future development of cancer-specific compendia. . 
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052910 doi: bioRxiv preprint first posted online May. 12, 2016; The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/052910 doi: bioRxiv preprint first posted online May. 12, 2016;  and breast cancer, respectively. Common significant genes between both tumour types (n=58) were further subdivided by their log hazard ratio, for each tumour type. Genes for which elevated expression levels are prognostic (HR>1) across both tumours, or genes for which down-regulated expression is prognostic (HR<1) are indicated. . 
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Enhancements in Data Assimilation and Annotation within MetaGxData
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Processing of Datasets
Final Assembly Figure 1 : Diagrammatic representation of the enhancements in data assimilation and annotation within the MetaGxData framework. The process of downloading a dataset, and subsequent curation, annotation and integration into MetaGxData is depicted.
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Breast Ovarian Figure 6 : Genome-wide assessment of the prognostic value of 11,346 genes common to both the MetaGxBreast and MetaGxOvarian datasets. A Venn diagram of significant genes (FDR<0.05) in each tumour following calculation of the Hazards Ratio is indicated (top). A total of 509 and 1,275 significantly prognostic genes were identified for ovarian and breast cancer, respectively. Common significant genes between both tumour types (n=58) were further subdivided by their log hazard ratio, for each tumour type. Genes for which elevated expression levels are prognostic (HR>1) across both tumours, or genes for which down-regulated expression is prognostic (HR<1) are indicated.
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